share_log

HC Wainwright & Co. Maintains Buy on TCR2 Therapeutics, Lowers Price Target to $13

Benzinga Real-time News ·  Nov 21, 2022 06:42

HC Wainwright & Co. analyst Robert Burns maintains TCR2 Therapeutics (NASDAQ:TCRR) with a Buy and lowers the price target from $14 to $13.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment